METTL3-mediated m6A modification promotes intervertebral disc degeneration
BACKGROUND: N-methyladenosine (mA) modification is a prevalent RNA modification in epigenetics. METTL3, acting as the principal methyltransferase responsible for catalysing mA, is regarded as a master regulator of this RNA modification. Nonetheless, the complex roles and underlying mechanisms of mA in relation to intervertebral disc degeneration (IDD) are yet to be fully elucidated. In light of this, this study aimed to explore the intricate functions and mechanisms of METTL3-mediated mA modification in IDD.66666
METHODS: Our previous batch of RNA sequencing data (GSE167199) and public single-cell data (GSE165722) were utilized to probe the relationship between mA-related genes and IDD. mA quantification, RNA mA immunoblotting, quantitative real-time PCR, western blot and immunofluorescent staining were used to validate the levels of mA modification and expression of mA-related genes in nucleus pulposus (NP) tissues and cells. Moreover, gain- and loss-of-function experiments in NP cells were conducted to explore the impact of METTL3 on IDD., the effects of METTL3 inhibition and miR-338-3p suppression on IDD progression were assessed.66666In vivo
RESULTS: A significant association between METTL3-mediated mA modification and IDD was identified. Overexpressing METTL3 induced apoptosis, accelerated senescence and inhibited matrix synthesis in NP cells. Additionally, METTL3-mediated mA modification could expedite the production and maturation of pri-miR-338-3p in NP cellsDGCR8., inhibiting METTL3 mitigated IDD progression, while suppressing miR-338-3p notably alleviated IDD during METTL3 overexpression.66viaIn vivo
CONCLUSIONS: This study reveals that targeting METTL3 attenuates IDD progression through the METTL3-mA-miR-338-3p axis, thereby highlighting the therapeutic potential of METTL3 inhibition for IDD. Future studies should prioritize the development of biomaterial delivery systems for METTL3 inhibitors to ensure both therapeutic protection and sustained, site-specific drug release.6